TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29775547

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beverage (NR; 12.8 mmol nitrate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrate-depleted placebo (PL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beverage (NR)
Number of subjects: 9
Study: 26747859

Group type: EXPERIMENTAL
Intervention: Ramucirumab + Paclitaxel
Number of subjects: 665

Group type: COMPARATOR
Intervention: Placebo + Paclitaxel
Number of subjects: 665
Study: 24119983

Group type: EXPERIMENTAL
Intervention: Bone Wax (BW)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Water-Soluble Wax (WSW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no hemostatic treatment)
Number of subjects: 50
Study: 21843930

Group type: EXPERIMENTAL
Intervention: Surgical deflators
Number of subjects: 129

Group type: COMPARATOR
Intervention: Medical deflators
Number of subjects: 129
Study: 20363504

Group type: EXPERIMENTAL
Intervention: 3.0‐mm CICS
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3.0‐mm SICS
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2.0‐mm CICS
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2.0‐mm SICS
Number of subjects: 90
Study: 17922725

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 40
Study: 16096246

Group type: EXPERIMENTAL
Intervention: Back to Fitness programme
Number of subjects: 237

Group type: COMPARATOR
Intervention: Individual physiotherapy
Number of subjects: 237
Study: 12386641

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated), 24 microg x kg(‐1) x h(‐1) for 96 hours
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study: 10446691

Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg twice daily (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 42
Study: 7768546

Group type: EXPERIMENTAL
Intervention: Oral typhoid vaccine (Ty21a)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 6
Study: 2311146

Group type: EXPERIMENTAL
Intervention: Plain lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine
Number of subjects: 20
Study: 911030

Group type: EXPERIMENTAL
Intervention: BCG adjuvant immunotherapy
Number of subjects: 100
Study: 30343376

Group type: EXPERIMENTAL
Intervention: Instrument-assisted stretching (IStr)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Perineal massage (PnM)
Number of subjects: 27
Study: 27225971

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delorme's operation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 50
Study: 25318650

Group type: EXPERIMENTAL
Intervention: New Forest Parenting Package (NFPP)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 164
Study: 23855973

Group type: EXPERIMENTAL
Intervention: 5 g/d of fish oil (providing 3 g of EPA + DHA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (corn and soybean oil)
Number of subjects: 12
Study: 16684856

Group type: EXPERIMENTAL
Intervention: Endurance training (9 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling exercise
Number of subjects: 8
Study: 15085909

Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Time Trade-Off (TTO)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Utility responses for hypothetical respondents
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Wearing glasses (health state)
Number of subjects: 31
Study: 10743982

Group type: EXPERIMENTAL
Intervention: Lansoprazole admixed with yogurt (regimen A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lansoprazole admixed with Ensure pudding (regimen B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lansoprazole admixed with cottage cheese (regimen C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intact lansoprazole capsule (regimen D)
Number of subjects: 24
Study: 8922766

Group type: EXPERIMENTAL
Intervention: 1 mg midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 500 micrograms alfentanil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5 mg midazolam plus 250 micrograms alfentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 1388952

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical oral hygiene (wooden interdental cleaner)
Number of subjects: 0
Study: 3894143

Group type: EXPERIMENTAL
Intervention: Caerulein (1 ng/kg . min infused intravenously over 15 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caerulein (i.v.)
Number of subjects: 24
Study: 31593122

Group type: EXPERIMENTAL
Intervention: Warm, humidified CO2 insufflation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20°C, 0% relative humidity CO2 with forced-air warmer set to 38°C
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dry CO2 insufflation (Group CE)
Number of subjects: 150
Study: 27433812

Group type: EXPERIMENTAL
Intervention: Gatorade and 357 g of PEG (day-prior dose)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Split-dose bowel preparations (3 different types)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Split-dose bowel preparations
Number of subjects: 1000
Study: 26398885

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioural intervention (GET.ON Mood Enhancer)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Enhanced care-as-usual (Control)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 406
Study: 24874401

Group type: EXPERIMENTAL
Intervention: MLSA‐LAM (1.0 µg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MLSA‐LAM (0.1 µg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MLCwA (1.0 µg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MLCwA (0.1 µg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MLSA‐LAM and MLCwA (both doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tuberculin PPD
Number of subjects: 90
Study: 21862698

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 11064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study: 19494158

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17223409

Group type: EXPERIMENTAL
Intervention: 20 mg of simvastatin
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 80 mg of simvastatin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 15646229

Group type: EXPERIMENTAL
Intervention: Filtek with Filtek Flow lining
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tetric Ceram with Tetric Flow lining
Number of subjects: 4

Group type: COMPARATOR
Intervention: Filtek
Number of subjects: 4

Group type: COMPARATOR
Intervention: Tetric Ceram
Number of subjects: 4
Study: 11368263

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal ovules (3-day treatment)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Clindamycin vaginal cream (7-day treatment)
Number of subjects: 384
Study: 9443537

Group type: EXPERIMENTAL
Intervention: d-amphetamine (5, 10 mg P.O.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam (2.5, 5 mg P.O.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tripelennamine (75 mg)
Number of subjects: 12
Study: 7977316

Group type: EXPERIMENTAL
Intervention: nitrendipine (10 to 40 mg/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: enalapril (5 to 20 mg/d)
Number of subjects: 16
Study: 2686418

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg intravenously every 12 hours
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ceftazidime 0.5 to 2 g intravenously every eight to 12 hours
Number of subjects: 86
Study: 31705581

Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray combined with 2% lidocaine gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution spray combined with 2% lidocaine gel
Number of subjects: 50
Study: 31711438

Group type: COMPARATOR
Intervention: Conventional surface landmark‐guided midline technique (group LM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Pre‐procedural US‐guided midline technique (group UM)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pre‐procedural US‐guided paramedian technique (group UP)
Number of subjects: 180
Study: 27957618

Group type: EXPERIMENTAL
Intervention: Corticosteroid local injection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Autologous whole blood
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 36
Study: 26070913

Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg every 12 hours for 24 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo to Ivacaftor
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ivacaftor to Ivacaftor
Number of subjects: 69
Study: 23933953

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg once daily (n = 12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg once daily (n = 12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 32
Study: 21799173

Group type: EXPERIMENTAL
Intervention: Cilostazol group (aspirin plus cilostazol)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Clopidogrel group (aspirin plus clopidogrel)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Cilostazol group
Number of subjects: 457

Group type: COMPARATOR
Intervention: Clopidogrel group
Number of subjects: 457
Study: 19508931

Group type: EXPERIMENTAL
Intervention: Web site for weight control (used over a 12-month period)
Number of subjects: 111
Study: 16847682

Group type: EXPERIMENTAL
Intervention: Neurology course (low patient-related teaching)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Otolaryngology course (high patient-related teaching)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Learning styles (strategic and deep)
Number of subjects: 111
Study: 15562366

Group type: COMPARATOR
Intervention: Canarypox vector-based HIV vaccines (ALVAC-HIV)
Number of subjects: 8
Study: 12815771

Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Mixed inhalation and intravenous anaesthesia
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia
Number of subjects: 184
Study: 9247978

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 125
Study: 8315424

Group type: COMPARATOR
Intervention: Doxorubicin 80 mg/m2
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Ifosfamide 7.5 g/m2 plus Doxorubicin 60 mg/m2
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Mitomycin 8 mg/m2 plus Doxorubicin 40 mg/m2 plus Cisplatin 60 mg/m2
Number of subjects: 279
Study: 3554564

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg daily for the first two weeks, then three times weekly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline solution intravenously)
Number of subjects: 24
Study: 30144731

Group type: EXPERIMENTAL
Intervention: Self-compassion intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Self-esteem intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Positive distraction control
Number of subjects: 153
Study: 26849410

Group type: EXPERIMENTAL
Intervention: Pain self-management (PSM) programme
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study: 24323178

Group type: EXPERIMENTAL
Intervention: Fully covered esophageal stent placement post-ESD (group A, n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No stent placement (group B, n = 11)
Number of subjects: 22
Study: 22189383

Group type: EXPERIMENTAL
Intervention: Cisplatin-based neoadjuvant chemotherapy (NAC)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Cystectomy only (Control)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Cisplatin-based neoadjuvant chemotherapy (NAC) with complete downstaging (CD)
Number of subjects: 449
Study: 20163382

Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU) combined with nicotine patches plus cognitive behavioral group counseling for smoking cessation (n = 153)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (n = 72)
Number of subjects: 225
Study: 20054187

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (24-week duration)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no weight loss intervention)
Number of subjects: 54
Study: 15813708

Group type: EXPERIMENTAL
Intervention: Nurse specialists in Parkinson's disease
Number of subjects: 1859
Study: 12433010

Group type: EXPERIMENTAL
Intervention: Pool Cool program (skin cancer prevention program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-matched injury-prevention control program
Number of subjects: 0
Study: 11344739

Group type: EXPERIMENTAL
Intervention: Ready-to-use formula
Number of subjects: 727

Group type: COMPARATOR
Intervention: Powdered formula
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Both ready-to-use and powdered formulas
Number of subjects: 727
Study: 8704116

Group type: COMPARATOR
Intervention: Intravenous calcitriol (2 micrograms after each dialysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral calcitriol (2 micrograms after each dialysis)
Number of subjects: 0
Study: 2072853

Group type: EXPERIMENTAL
Intervention: Quinine chemoprophylaxis
Number of subjects: 61

Group type: COMPARATOR
Intervention: No quinine chemoprophylaxis (Control)
Number of subjects: 61
Study: 6414795

Group type: EXPERIMENTAL
Intervention: Oral long-term treatment with antiarrhythmic drugs (aprindine, mexiletine, disopyramide, amiodarone)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 82
Study: 31919123

Group type: EXPERIMENTAL
Intervention: Infusion of activated and expanded haploidentical NK (NKAE) cells, two doses once a week, using a GMP K562‐mbIL15‐41BBL stimulus from a haploidentical donor and interleukin 2 subcutaneously.
Number of subjects: 0
Study: 30575616

Group type: EXPERIMENTAL
Intervention: Office-based accommodative/vergence therapy (OBAVT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 34
Study: 29078971

Group type: EXPERIMENTAL
Intervention: Acupuncture with real needle penetration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment without needle penetration
Number of subjects: 0
Study: 25730341

Group type: EXPERIMENTAL
Intervention: Interoceptive exposure (IE) through running, following a 3-day group cognitive behavioral therapy intervention.
Number of subjects: 28
Study: 23828333

Group type: EXPERIMENTAL
Intervention: 8-week standardized yoga protocol (Viniyoga tradition), 45-minute sessions once per week and home practice
Number of subjects: 9
Study: 21816050

Group type: EXPERIMENTAL
Intervention: WHO Essential Newborn Care (ENC) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonatal Resuscitation Program (NRP) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Before ENC training
Number of subjects: 0
Study: 19183083

Group type: EXPERIMENTAL
Intervention: Routine screening for intimate partner violence (IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asking about IPV in differential diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: CDC randomized controlled trial
Number of subjects: 0
Study: 16518519

Group type: EXPERIMENTAL
Intervention: Oxerutins (2 g/day)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Daflon (3 tablets of 500 mg daily for 8 weeks)
Number of subjects: 212
Study: 12680524

Group type: EXPERIMENTAL
Intervention: HME with fresh gas flow of 1L/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HME with fresh gas flow of 3L/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fresh gas flow of 1L/min without HME
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fresh gas flow of 3L/min without HME
Number of subjects: 40
Study: 9952054

Group type: EXPERIMENTAL
Intervention: Increased frequency in performing low‐fat eating behaviors
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Percentage calories from fat intake
Number of subjects: 301
Study: 8669217

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study: 2179027

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 501487

Group type: EXPERIMENTAL
Intervention: Ten-session weight reduction program including behavior modification, nutrition education, and exercise management
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study: 7050331

Group type: EXPERIMENTAL
Intervention: Group 1 - fluids managed to allow 1 to 2% loss of BW per day to a maximum loss of 8 to 10%
Number of subjects: 88

Group type: COMPARATOR
Intervention: Group 2 - fluids managed to allow 3 to 5% loss of BW per day to a maximum loss of 13 to 15%
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 88
Study: 29786959

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg with Sitagliptin 100 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg with Metformin 1000 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg with Glimepiride 1 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg with Simvastatin 40 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 66
Study: 26160548

Group type: EXPERIMENTAL
Intervention: Jasmine rice (JR)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Basmati rice (BR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Number of chews per mouthful (JR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Number of chews per mouthful (BR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chewing time per mouthful (JR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chewing time per mouthful (BR)
Number of subjects: 75
Study: 24559217

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 235
Study: 21703829

Group type: EXPERIMENTAL
Intervention: Cranberry juice, twice a day for 6 weeks (including 2 weeks post-treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage, twice a day for 6 weeks (including 2 weeks post-treatment)
Number of subjects: 0
Study: 20110568

Group type: EXPERIMENTAL
Intervention: Carrying more than 22 risk-alleles
Number of subjects: 3925

Group type: EXPERIMENTAL
Intervention: 20 SNPs combined with conventional nongenetic risk factors
Number of subjects: 3925
Study: 18037444

Group type: EXPERIMENTAL
Intervention: Transition to Community program, involving interviews by an advanced practice psychiatric nurse, communication via prepaid cellular phones, and follow-up on medication compliance and outpatient appointments.
Number of subjects: 13
Study: 16096584

Group type: EXPERIMENTAL
Intervention: DIBrH SPECT images
Number of subjects: 28
Study: 12381235

Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy in elderly patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment and therapy guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral drug dosage adjustment
Number of subjects: 0
Study: 10525248

Group type: EXPERIMENTAL
Intervention: VENTAK AV device
Number of subjects: 69

Group type: COMPARATOR
Intervention: VENTAK MINI device (control)
Number of subjects: 69
Study: 7723928

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2025037

Group type: EXPERIMENTAL
Intervention: Airway pressure trigger
Number of subjects: 10

Group type: COMPARATOR
Intervention: Graseby MR10 respiration monitor
Number of subjects: 10
Study: 6449902

Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin, 260 mg/kg/day in six divided doses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin, 450 mg/kg/day in six divided doses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined results from both dosage regimens
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 23
Study: 29600400

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 630

Group type: COMPARATOR
Intervention: fesoterodine 4 mg
Number of subjects: 630
Study: 30296323

Group type: EXPERIMENTAL
Intervention: Time-to-surgery <24 hours
Number of subjects: 6036

Group type: EXPERIMENTAL
Intervention: Time-to-surgery 24-48 hours
Number of subjects: 6036

Group type: COMPARATOR
Intervention: Time-to-surgery >48 hours
Number of subjects: 6036

Group type: EXPERIMENTAL
Intervention: Time-to-surgery
Number of subjects: 6036
Study: 27693901

Group type: EXPERIMENTAL
Intervention: Stop-and-go methadone titration method
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Progressive methadone titration method
Number of subjects: 146

Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 146
Study: 24225312

Group type: EXPERIMENTAL
Intervention: Cold pack
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hot pack
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no thermal agent)
Number of subjects: 24
Study: 22325080

Group type: EXPERIMENTAL
Intervention: Monoamine depletion (acute combined tryptophan, tyrosine, and phenylalanine depletion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Balanced condition (consumption of a beverage containing tryptophan, tyrosine, and phenylalanine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Monoamine depletion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Balanced condition
Number of subjects: 12